We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
+7.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
+$6.95M
(+5.8%)
Cap. Flow
-$1.04M
Cap. Flow
% of AUM
-0.83%
Top 10 Holdings %
Top 10 Hldgs %
37.72%
Holding
74
New
9
Increased
25
Reduced
7
Closed
17
Avg Time Held Equity + Options
1.5
quarters
Top 10 Avg Time Held Equity + Options
0.8
quarters
Top 20 Avg Time Held Equity + Options
1.6
quarters
Avg Time Held Equity only
1.6
quarters
Top 10 Avg Time Held Equity only
0.8
quarters
Top 20 Avg Time Held Equity only
1.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$3.42M |
| 2 |
ProShares Ultra NASDAQ Biotechnology
BIB
|
+$1.55M |
| 3 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$1.03M |
| 4 |
Pacira BioSciences
PCRX
|
+$949K |
| 5 |
Array Biopharma Inc
ARRY
|
+$886K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
+$4.15M |
| 2 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$3.48M |
| 3 |
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
|
+$1.73M |
| 4 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$912K |
| 5 |
Tenax Therapeutics
TENX
|
+$812K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.86% |
| 2 | Miscellaneous | 16.89% |
| 3 | Financials | 0.25% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
RCPT
1
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $5.34M | 4.23% |
28,124
+2,445
| +10% | +$404K |
2014 Q4
2 quarters
|
|
|
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.05M | 4% |
104,339
-6,711
| -6% | -$277K |
2014 Q4
2 quarters
|
|
3
BioMarin Pharmaceuticals
BMRN
$10.7B
| $4.91M | 3.89% |
35,899
+3,354
| +10% | +$416K |
2014 Q4
2 quarters
|
|
|
4
ProShares Ultra NASDAQ Biotechnology
BIB
$91.4M
| $4.84M | 3.83% |
53,568
+18,000
| +51% | +$1.55M |
2014 Q4
2 quarters
|
|
5
Illumina
ILMN
$41.8B
| $4.68M | 3.71% |
22,052
+866
| +4% | +$169K |
2014 Q4
2 quarters
|
|
|
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
| $4.61M | 3.65% |
52,400
-3,588
| -6% | -$307K |
2014 Q4
2 quarters
|
|
7
Nektar Therapeutics
NKTR
$1.36B
| $4.6M | 3.65% |
24,531
+2,154
| +10% | +$371K |
2014 Q4
2 quarters
|
|
8
Alkermes
ALKS
$6.75B
| $4.57M | 3.62% |
71,022
+8,476
| +14% | +$519K |
2014 Q4
2 quarters
|
|
9
Biogen
BIIB
$33.9B
| $4.55M | 3.6% |
11,254
+1,923
| +21% | +$772K |
2014 Q4
2 quarters
|
|
10
Regeneron Pharmaceuticals
REGN
$78.5B
| $4.47M | 3.54% |
8,759
+9
| +0.1% | +$4.39K |
2014 Q4
2 quarters
|
|
|
CELG
11
DELISTED
Celgene Corp
CELG
| $4.44M | 3.52% |
38,375
+5,086
| +15% | +$581K |
2014 Q4
2 quarters
|
|
12
Incyte
INCY
$22.6B
| $4.36M | 3.46% |
41,873
-1,809
| -4% | -$187K |
2014 Q4
2 quarters
|
|
13
Vertex Pharmaceuticals
VRTX
$129B
| $4.36M | 3.45% |
35,276
+2,471
| +8% | +$311K |
2014 Q4
2 quarters
|
|
14
Alnylam Pharmaceuticals
ALNY
$30.4B
| $4.19M | 3.32% |
34,979
-2,409
| -6% | -$288K |
2014 Q4
2 quarters
|
|
|
MDVN
15
DELISTED
MEDIVATION, INC.
MDVN
| $3.92M | 3.11% |
68,688
+7,194
| +12% | +$443K |
2014 Q4
2 quarters
|
|
|
CPHD
16
DELISTED
Cepheid Inc
CPHD
| $3.89M | 3.08% |
63,635
+8,942
| +16% | +$510K |
2014 Q4
2 quarters
|
|
|
ALXN
17
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.88M | 3.07% |
21,474
-557
| -3% | -$96.1K |
2014 Q4
2 quarters
|
|
18
Ionis Pharmaceuticals
IONS
$7.26B
| $3.81M | 3.02% |
66,208
+5,296
| +9% | +$337K |
2014 Q4
2 quarters
|
|
19
Mettler-Toledo International
MTD
$31.3B
| $3.76M | 2.97% |
11,000
+1,564
| +17% | +$515K |
2014 Q4
2 quarters
|
|
|
QGENF
20
DELISTED
QIAGEN NV
QGENF
| $3.47M | 2.75% |
140,000
+17,276
| +14% | +$428K |
2014 Q4
2 quarters
|
|
21
Bio-Techne
TECH
$11.4B
| $3.35M | 2.65% |
136,000
+12,332
| +10% | +$308K |
2014 Q4
2 quarters
|
|
|
22
Pacira BioSciences
PCRX
$1.45B
| $3.32M | 2.63% |
47,000
+12,051
| +34% | +$949K |
2015 Q1
1 quarter
|
|
|
23
AstraZeneca
AZN
$246B
| $3.19M | 2.52% |
+50,000
| New | +$3.42M |
2015 Q2
0 quarters
|
|
|
24
DELISTED
Array Biopharma Inc
ARRY
| $2.31M | 1.83% |
320,000
+120,000
| +60% | +$886K |
2014 Q4
2 quarters
|
|
25
DELISTED
Hologic
HOLX
| $1.83M | 1.45% |
48,000
-2,000
| -4% | -$70K |
2014 Q4
2 quarters
|
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q2 2015 Portfolio in Review
As of Q2 2015, Opus Point Partners Management held 74 positions worth $126M, up 5.8% from $119M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Opus Point Partners Management's Q2 2015 filing shows 9 new, 25 increased, 7 reduced and 17 closed positions. Its largest new stake was AstraZeneca: 50,000 shares worth $3.19M. The largest sale was SALIX PHARMACEUTICALS LTD DEL, an estimated $4.15M.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 78% a quarter earlier, followed by Miscellaneous and Financials.
- Opus Point Partners Management's largest Q2 2015 buy was AstraZeneca: 50,000 shares worth $3.19M.
- Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2015, an estimated $1.55M increase.
- Opus Point Partners Management's biggest Q2 2015 reduction was Clovis Oncology, Inc., cutting an estimated $307K.
- Opus Point Partners Management fully exited SALIX PHARMACEUTICALS LTD DEL in Q2 2015, selling an estimated $4.15M.
- Opus Point Partners Management's ten largest holdings make up 38% of its $126M portfolio in Q2 2015.
- Opus Point Partners Management opened 9 new positions and closed 17 in Q2 2015.
- Opus Point Partners Management's portfolio value rose 5.8% quarter-over-quarter to $126M.
Based on Opus Point Partners Management's 13F filing for Q2 2015, filed 14 Aug 2015.